Announcements Trials
Browse Landscape

Phase

Phase NA 5Phase 1 3Phase 2 2Phase 1/2 1

Status

Not yet recruiting 1Completed 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 2

Sponsor

Cancer Type

Breast 2

Conditions

Breast Neoplasms 2767Triple Negative Breast Neoplasms 406Neoplasm Metastasis 156Breast Neoplasms, Male 102Neoplasms 100Ovarian Neoplasms 69Carcinoma, Non-Small-Cell Lung 68Carcinoma, Intraductal, Noninfiltrating 68Lung Neoplasms 66Brain Neoplasms 60Colorectal Neoplasms 52Inflammatory Breast Neoplasms 50Advanced Breast Cancer 48Breast Carcinoma In Situ 47Prostatic Neoplasms 42Melanoma 38Pancreatic Neoplasms 37Stomach Neoplasms 32Uterine Cervical Neoplasms 28Sarcoma 27HER2-positive Breast Cancer 27Endometrial Neoplasms 25Head and Neck Neoplasms 24Recurrence 23Colonic Neoplasms 22Carcinoma, Renal Cell 21Carcinoma, Ovarian Epithelial 21Small Cell Lung Carcinoma 20Multiple Myeloma 20Carcinoma, Ductal, Breast 20

Interventions

exemestane 1Tamoxifen 1Pemetrexed 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × Carcinoma, Ductal × Breast × Clear all
NCT07499999 2026-03-30

BabyTEARS

Dana-Farber Cancer Institute

Phase 2 Not yet recruiting
140 enrolled
Breast

Breast Neoplasms, Carcinoma, Ductal

NCT00106002 2009-06-01

Pemetrexed as the First Treatment in Advanced or Metastatic Breast Cancer

Eli Lilly and Company

Phase 2 Completed
37 enrolled 9 charts
Breast

Breast Neoplasms, Breast Neoplasms, Male, Carcinoma, Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡